ACP
Acuta Capital Partners Portfolio holdings
AUM
$71.6M
This Quarter Return
-4.76%
1 Year Return
+169.78%
3 Year Return
+1,553.75%
5 Year Return
+4,509.01%
10 Year Return
+155,159.98%
AUM
$86.2M
AUM Growth
+$86.2M
(-13%)
Cap. Flow
-$1.2M
Cap. Flow
% of AUM
-1.39%
Top 10 Holdings %
Top 10 Hldgs %
64.54%
Holding
46
New
7
Increased
19
Reduced
6
Closed
12
Top Buys
| 1 |
Soleno Therapeutics
SLNO
|
$4.8M |
| 2 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$2.78M |
| 3 |
Oculis Holding
OCS
|
$2.38M |
| 4 |
Merck
MRK
|
$2.06M |
| 5 |
Surrozen
SRZN
|
$1.98M |
Top Sells
| 1 |
Crinetics Pharmaceuticals
CRNX
|
$6.28M |
| 2 |
Vaxcyte
PCVX
|
$3.68M |
| 3 |
Mersana Therapeutics
MRSN
|
$1.6M |
| 4 |
Revolution Medicines
RVMD
|
$1.59M |
| 5 |
Taysha Gene Therapies
TSHA
|
$1.53M |
Sector Composition
| 1 | Healthcare | 99.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $8.94M | 10.37% | 1,219,724 +108,653 | +10% | +$796K |
|
2
Insmed
INSM
$28.8B
| $8.09M | 9.38% | 106,074 +1,274 | +1% | +$97.2K |
|
3
Tourmaline Bio
TRML
$601M
| $6.49M | 7.53% | 426,882 +75,040 | +21% | +$1.14M |
|
|
WHWK
4
Whitehawk Therapeutics, Inc. Common Stock
WHWK
$84.8M
| $6.07M | 7.04% | 3,410,402 +1,561,000 | +84% | +$2.78M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $5.22M | 6.05% | 265,269 -2,099 | -0.8% | -$41.3K |
|
6
Trevi Therapeutics
TRVI
$883M
| $4.94M | 5.73% | 785,961 +14,003 | +2% | +$88.1K |
|
|
7
Soleno Therapeutics
SLNO
$3.6B
| $4.8M | 5.56% | +67,136 | New | +$4.8M |
|
8
argenx
ARGX
$43.6B
| $4.16M | 4.82% | 7,023 +113 | +2% | +$66.9K |
|
9
Ascendis Pharma
ASND
$11.8B
| $3.64M | 4.22% | 23,340 +364 | +2% | +$56.7K |
|
10
Praxis Precision Medicines
PRAX
$958M
| $3.3M | 3.83% | 87,141 +19,641 | +29% | +$744K |
|
11
Cidara Therapeutics
CDTX
$1.66B
| $2.71M | 3.14% | 125,708 +71,235 | +131% | +$1.53M |
|
|
12
Oculis Holding
OCS
$844M
| $2.38M | 2.76% | +125,000 | New | +$2.38M |
|
|
13
Revolution Medicines
RVMD
$7.1B
| $2.36M | 2.73% | 66,662 -45,038 | -40% | -$1.59M |
|
14
Liquidia Corp
LQDA
$2.38B
| $2.26M | 2.63% | 153,482 +15,773 | +11% | +$233K |
|
|
DRUG
15
Bright Minds Biosciences
DRUG
$276M
| $2.16M | 2.5% | 59,748 -9,376 | -14% | -$338K |
|
|
BBOT
16
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $2.12M | 2.45% | 187,257 +6,312 | +3% | +$71.3K |
|
|
17
Merck
MRK
$210B
| $2.06M | 2.39% | +22,994 | New | +$2.06M |
|
|
18
Surrozen
SRZN
$104M
| $1.98M | 2.3% | +170,000 | New | +$1.98M |
|
19
Edgewise Therapeutics
EWTX
$1.51B
| $1.88M | 2.18% | 85,454 -2,204 | -3% | -$48.5K |
|
|
MREO
20
Mereo BioPharma
MREO
$272M
| $1.78M | 2.07% | 791,815 +12,507 | +2% | +$28.1K |
|
21
Unicycive Therapeutics
UNCY
$74M
| $1.35M | 1.57% | 2,352,887 +49,887 | +2% | +$28.7K |
|
22
Jazz Pharmaceuticals
JAZZ
$7.75B
| $1.19M | 1.38% | +9,575 | New | +$1.19M |
|
23
Verastem
VSTM
$569M
| $1.06M | 1.23% | +176,000 | New | +$1.06M |
|
24
Gilead Sciences
GILD
$140B
| $1.04M | 1.21% | 9,298 +148 | +2% | +$16.6K |
|
25
Terns Pharmaceuticals
TERN
$609M
| $899K | 1.04% | 325,550 -121,950 | -27% | -$337K |
|